Alteogen Shares Rise on Filing of Securities Registration for Merger with Alteogen Biologics
Alteogen (196170) is showing strength in the morning session on the 14th. As of 11:09 a.m., the stock is trading at 227,000 won, up 2,500 won (+1.11%) from the previous day. The market attention stems from a disclosure released today. Alteogen is proceeding with a process to absorb its subsidiary A

Alteogen (196170) is showing strength in the morning session on the 14th. As of 11:09 a.m., the stock is trading at 227,000 won, up 2,500 won (+1.11%) from the previous day.
The market attention stems from a disclosure released today. Alteogen is proceeding with a process to absorb its subsidiary Alteogen Biologics through merger, under which it plans to issue 600,477 new common shares. The additional listing date for the merger shares is scheduled for January 25, 2027.
■ Small-Scale Merger Method... Total New Share Issuance of 156.9 Billion Won
According to the securities registration statement submitted by Alteogen on the 14th, the merger will proceed as a small-scale merger with Alteogen as the surviving company and Alteogen Biologics as the dissolving company.
The securities to be offered or sold are 600,477 registered common shares of Alteogen, with a total offering amount of 156,931,661,565 won. The new shares to be issued in the merger account for approximately 0.85% of the total 70,784,440 shares to be issued after the merger.
As of the date of the securities registration statement filing, Alteogen holds 80.69% of Alteogen Biologics' common shares. Its stake based on all issued shares including convertible preferred shares is 62.89%.
Upon completion of the merger, all businesses, assets and liabilities, and rights and obligations of Alteogen Biologics will be comprehensively succeeded by Alteogen. However, the scale of new share issuance and the number of shares issued after the merger may change depending on the exercise of dissenting shareholders' appraisal rights and the treatment of fractional shares.
■ Board Resolution to Replace Shareholder Approval... Possibility of Merger Delay or Cancellation
Regarding the merger process, Alteogen plans to replace shareholder approval with a board resolution under the small-scale merger provisions of the Commercial Act. Meanwhile, Alteogen Biologics must pass a special resolution at a shareholders' meeting to approve the merger agreement.
If objections from shareholders meeting certain criteria occur or the shareholders' meeting fails to approve the merger, the merger schedule may be delayed or the merger may fall through.
■ ALT-L9 Business to Be Integrated into Alteogen... "Expectations for Management and Investment Efficiency"
Through this merger, the two companies plan to integrate research and development, clinical and regulatory affairs, sales and marketing organizations, and fund management.
Alteogen Biologics has been conducting global clinical trials, regulatory approval, and domestic and overseas sales-related businesses for ALT-L9, a biosimilar of Eylea. After the merger, these businesses will be integrated into Alteogen.
Alteogen stated in the securities registration statement that it expects improved management and investment efficiency through the integration of human and material resources and the concentration of internal capabilities after the merger. However, it also noted as an investment risk that its financial condition and business performance could be affected depending on the progress of the merger process and the business integration process.
[※ This article is intended to convey market trends and is not intended to recommend investment in any specific stock.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



